Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of tulisokibart in moderately to severely active Crohn's disease
2023-508636-61-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing tulisokibart with placebo (2 arms). Planned start Oct 2024; status: authorised.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-508636-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508636-61-00.